Evidence network for deaths_(OS)

1CALGB 40302, 20141EGF30008 (HER2-positive), 20091PENELOPE-B, 20211MONALEESA-2, 20161PALOMA-1, 20161SYSUCC-002, 2022aromatase inhibitorfulvestrantletrozoleendocrine therapypaclitaxelexemestane plus ridaforolimustrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitorlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus endocrine therapyribociclib plus letrozoleabemaciclib plus endocrine therapypalbociclib plus letrozoleipatasertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanetrastuzumab plus endocrine therapycediranib plus fulvestrantdirect evidencenetwork meta-analysis
T vs. C aromatase inhibitorfulvestrantletrozoleendocrine therapypaclitaxelexemestane plus ridaforolimustrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitorlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus endocrine therapyribociclib plus letrozoleabemaciclib plus endocrine therapypalbociclib plus letrozoleipatasertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanetrastuzumab plus endocrine therapycediranib plus fulvestrant
aromatase inhibitor---NANANANANANANANANANANANANANANANANANA
fulvestrantNA---NANANANANANANANANANANANANANANANANA
letrozoleNANA---NANANANANANANANANANANANANANANANA
endocrine therapyNANANA---NANANANANANANANANANANANANANANA
paclitaxelNANANANA---NANANANANANANANANANANANANANA
exemestane plus ridaforolimusNANANANANA---NANANANANANANANANANANANANA
trastuzumab plus chemotherapyNANANANANANA---NANANANANANANANANANANANA
abemaciclib plus aromatase inhibitorNANANANANANANA---NANANANANANANANANANANA
lapatinib plus fulvestrantNANANANANANANANA---NANANANANANANANANANA
lapatinib plus letrozoleNANANANANANANANANA---NANANANANANANANANA
palbociclib plus endocrine therapyNANANANANANANANANANA---NANANANANANANANA
ribociclib plus letrozoleNANANANANANANANANANANA---NANANANANANANA
abemaciclib plus endocrine therapyNANANANANANANANANANANANA---NANANANANANA
palbociclib plus letrozoleNANANANANANANANANANANANANA---NANANANANA
ipatasertib plus paclitaxelNANANANANANANANANANANANANANA---NANANANA
capivasertib plus paclitaxelNANANANANANANANANANANANANANANA---NANANA
dalotuzumab plus ridaforolimus plus exemestaneNANANANANANANANANANANANANANANANA---NANA
trastuzumab plus endocrine therapyNANANANANANANANANANANANANANANANANA---NA
cediranib plus fulvestrantNANANANANANANANANANANANANANANANANANA---

pathologies: 352,354 - treatments: 1447 result logic